Amplifctin of the human N-myc protooncogene, MYCN, Is 
Amplification is one of the mechanisms by which cellular oncogenes can be activated to express abnormally high levels of protein and to participate in tumorigenesis (1) . The most consistent pattern is seen for human neuroblastoma, where the gene MYCN has been found amplified in both tumors and cell lines (2, 3) . Amplification of MYCN is correlated with aggressive tumor growth (4) and is a predictor for clinical outcome of the patient (ref. 5 ; for review, see ref. 6) .
MYCN maps to chromosome 2 band p23-24 (7) . Amplified copies of MYCN localize to two types of chromosomal abnormalities, double minutes (DMs; ref. 3 ) and homogeneously staining regions (HSRs; refs. [7] [8] [9] [10] . Neither the resident site of MYCN nor other regions of the short (p) arm of chromosome 2 have been found to harbor amplified MYCN. This implies that the evolution of HSR involves the transposition of MYCN from its original location to distant chromosomal sites (3) .
Although early events of MYCN amplification remain elusive, the question ofwhether MYCN is retained or deleted at its original location can be addressed. We have employed fluorescence in situ hybridization to determine the status of single-copy MYCN in five neuroblastoma cell lines. We found in all cases that MYCN was present on both apparently unrearranged chromosomes 2. The heterozygosity of microsatellite loci established that the two chromosomes 2 heated for 5 min at 950C and 1 unit of DNA polymerase from Thermus aquaticus (Taq DNA polymerase) was added to initiate a "hot start." Reaction conditions were 950C for 30 sec, 550C for 75 sec, and 74WC for 30 sec for each cycle. The cycle was repeated 29 times with a final extension of 3 min at 74WC. Two microliters of the reaction mix was electrophoresed in a denaturing 5% polyacrylamide sequencing gel. The gel was dried and exposed for 12 hr to Kodak x-ray film. Sequences of primers were as described (20) . The location of MYCN was determined in two-color analyses. MYCN cosmid pNb-101 was labeled with biotin, and the probe specific for the centromere of chromosome 2 was labeled with digoxygenin. Analyses of metaphases from a lymphocyte culture confirmed that the expected signals for MYCN were recorded ( Fig. 2A, green) . The centromere probe identified the two copies of chromosome 2 ( Fig. 2 B-F,  red) .
RESULTS
Analyses of metaphases from the neuroblastoma cells revealed the presence of MYCN on the two copies of chromosome 2 in all five lines (Fig. 2 B-F Presence of Two Homologous Chromosomes 2. To find out whether the two copies of chromosome 2 present in the neuroblastoma lines represented the parental homologous chromosomes, we analyzed five microsatellite loci consisting of (CA). repeats (20) from the p arm, located on the distal and proximal side of MYCN, and from two loci from the q arm. To detect polymorphism we used PCR primers corresponding to sequences on either side of the (CA). repeat (21) . Line NGP was heterozygous for seven loci tested (Fig. 3) . IMR-32 and LS were heterozygous for five loci and LAN-S and HD-MG-1 for four loci (Table 1 ). These data demonstrate that the two copies of chromosome 2 are different and therefore represent the two parental homologs.
Coamplificatlon of MYCN with Host Chromosomal DNA in a HSR. The two HSRs in LS are integrated in chromosome 12 (14) . The roughly 100 copies of MYCN (14) are present within amplicons of relatively small size (11) . To determine the composition of this HSR we employed fluorescence in situ hybridization using MYCN and a whole chromosome 12 library as probes. Cohybridization ofthe two probes revealed a scattered signal for MYCN over the HSR and for the chromosome 12 library both over the chromosome 12 and HSR sequences (Fig. 4A) . With the chromosome 12 library as a probe, we again saw a signal both on the two complete .ii~~~~~zl~~~nl-
derivative chromosomes 12 and on the intact chromosome 12 (Fig. 4B ). These data demonstrate that chromosome 12 DNA is coamplified with MYCN.
To determine the complexity of the amplified chromosome 12 DNA, we labeled total DNA from LS and hybridized this probe to metaphase chromosomes of normal lymphocytes (Fig. 4C) . A strong signal was seen on both copies of chromosome 12 around band q14. We did not detect a signal for MYCN on chromosome 2, presumably because of the low amount of DNA in the HSR derived from the MYCN locus. For comparison we used the same approach with DNA from line HD-MG-1, which contains DMs. A signal was detected on both copies of chromosome 2 at the site of the MYCN locus (Fig. 4D) . In contrast to LS, we could not detect amplified sequences other than those derived from the MYCN locus.
DISCUSSION
Although amplification is a common route by which cellular oncogenes can become activated, little is known about the molecular mechanism involved. The inherent problem is that only the end point ofthe amplification process can be studied, from which it is impossible to draw firm conclusions about which MYCN becomes amplified. Alternatively, it cannot be excluded that MYCN in this single case analyzed was deleted at some time during the somatic cell fusions used to demonstrate deletion. This latter possibility could be addressed through direct inspection ofMYCNin the parental cell line by fluorescence in situ hybridization.
Several mechanisms that have been proposed to account for unscheduled gene amplification, most of which are based on drug-resistance models. Early proposals suggested that repeated initiation ofDNA replication at a single origin within a cell cycle leads to an "onionskin" structure (25) , similar to that seen during developmentally regulated chorion gene amplification in Drosophila (26) . This structure could be resolved through recombination into intra-or extrachromosomal DNA (25) . Inspection of early events by chromosomal in situ hybridization, however, has revealed that initial products of drug-resistance gene amplification can be tens of megabases long (27) (28) (29) and therefore too large to fit extrareplication models. The initial event proposed to account for the duplication of large regions, particularly in the amplification of the carbamoyl-phosphate synthetase 2/aspartate carbamoyltransferase/dihydroorotase gene (28) and the adenylate deaminase 2 gene (30), is based on telomeric fusions and bridge-breakage-fusion cycles (28) . Expansion of the initial duplication could subsequently lead to multiplication. As a key feature the amplified gene copies would reside on the same chromosome arm that carries the single-copy gene with the gene present in its normal position in the marker chromosome (27) (28) (29) (30) . It is interesting that the amplified gene copies even after long-term selection usually remain on the same chromosome where the single-copy gene is localized (29, 31) , although the complexity of the amplified structures may be condensed by relatively infrequent secondary events (28) . As an alternative model for initial events of drugresistance, gene amplification chromosome breakage and deletion have been suggested to play a central role during amplification (32) . Chromosome breakage is assumed to occur within a stalled replication bubble and could lead to a centric element observed during early events ofamplification of the dihydrofolate reductance gene in a Chinese hamster ovary cell line (32) . A particular feature of this proposed pathway is that an early event during amplification creates a chromosomal architecture in which the single-copy gene is prone to deletion. The report of MYCN deletion from one copy ofchromosome 2 in human neuroblastoma line N0315L (24) has been interpreted as in support of the chromosome breakage-and-deletion model (32) .
From results presented here and from previously published data (11) (11, 33) . The latter is in contrast to the presence of inverted rearranged units found in stable cell lines carrying a highly amplified adenylate deaminase 2 gene as the result of multiple selection steps (34) and the inverted repeats seen widely in other models (35) (36) (37) . Even though we cannot determine directly the initial events during MYCN amplification, it seems intuitively unlikely that it follows pathways observed for the amplification of drug-resistance genes. Initial events by telomeric fusion and bridge-breakagefusion cycles are not supported by the presence of the two apparently intact parental homologs of chromosome 2, at least there is no indication that large duplicated, or multiplicated, copies of the MYCN locus had ever developed at 2p. Ifthey had developed initially, they would have to be excised in all cases with great precision to leave the original chromosomes 2 intact. Our analyses for microsatellite loci and the in situ hybridization with the MYCN probe did not reveal deletion or structural rearrangements at the very distal end of 2p that should accompany intrachromosomal multiplication followed by excision of the amplified sequences. Also, we have no reason to assume a selective force favoring elimination of amplified copies from 2p. The chromosome breakage-deletion mechanism appears also unlikely as an initial step toward amplification, because our data show the presence of MYCN on both of the homologous parental chromosomes.
The evolution of the HSR in line LS involves coamplification of MYCN together with host-chromosome DNA. We have yet to determine whether the HSRs in other cell lines result from coamplification ofMYCN with the corresponding host-chromosome sequences. Detection ofcoamplification in line LS apparently was facilitated by the huge amount of host DNA amplified together with MYCN. The limited sensitivity ofthe reverse painting approach for detecting amplified DNA is illustrated by our inability to detect amplified MYCN. It is possible that HSRs in other lines also contain amplified host DNA, but the amount might be too low to allow detection by employing in situ hybridization with whole chromosomes libraries or by reverse painting approaches.
We conclude that it is presently impossible to delineate initial events of MYCN amplification. However, the results presented here enhance the idea that MYCN amplification follows a mechanism that is different from those leading to amplification of drug-resistance genes. 
